OFT refers Alliance Medical acquisition

Alliance Medical’s acquisition of IBA Molecular has been referred to the Competition Commission by the Office of Fair Trading (OFT). Alliance acquired the company in September 2013 in a move to secure the future UK production of the vital pharmaceutical that allows PET/CT scanning – Fluorodeoxyglucose 18F (FDG-18). The deal was supported by investors and the Department of Health and saw Alliance take on IBA Molecular’s FDG production facility, gaining a licensing agreement to supply Alliance PET/CT centres in Italy, Germany and Spain. IBA Molecular continued its other UK nuclear medicine manufacturing activities as well as its FDG business in the rest of Europe.